Patent ID: 9629847
Date: 2017-04-25
CPC Classifications: A61K,A61P

Claim:
1. A method of treating symptoms of tumor necrosis factor (TNF) mediated inflammation by inhibiting TNF in a mammal, as measurable using assays that measure inhibition of TNF alpha levels in blood, plasma or tissues of the mammal; and wherein the TNF inhibition is not attributable to anti-histamine activity alone in the mammal, in the mammal in need thereof, the method comprising: (a) administering to the mammal every 4-12 hours a TNF inhibiting pharmaceutically effective amount of a composition comprising: wherein the TNF inhibiting pharmaceutically effective amounts have been determined to be sufficient to inhibit TNF in the mammal as measured using the TNF inhibition assay that measures the inhibition of TNF alpha levels in the blood, plasma or tissues of the mammal; and wherein said TNF inhibition is not attributable to anti-histamine activity alone in the mammal.